Developer docs
API playgroundTry for free, no card

Search company profiles

Neovirtech

Full company profile

uuid000vkwu

Namestring
Neovirtech
Legal namestring
NeoVirTech SAS
Websiteurl
neovirtech.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

NeoVirTech SAS is a French biotechnology Contract Research Organization (CRO) founded in February 2014 and headquartered at the Oncopole campus in Toulouse, with an additional R&D laboratory at the Toulouse Cancer Research Center (CRCT) opened in 2022. The company commercializes its proprietary ANCHOR™ DNA tagging technology — a system that fuses a short non-repetitive ANCH sequence with an OR-fluorescent protein to convert any dsDNA virus or vector into an autofluorescent particle, enabling autonomous real-time visualization of viral infection and replication in living cells without fixation, extraction, or staining. Multiple ANCHOR™ systems (up to four colors) can be operated simultaneously for co-infection studies, and the company maintains a catalog of 32 ANCHOR-tagged viruses spanning human, animal, and biodefense applications. Core technical infrastructure includes dual BSL2/BSL3 containment, automated CellInsight CX7 HCS high-content screening, pipetting robots, and a 22TB secured server, all of which underwrite both internal R&D and customer service delivery.

The company monetizes through three revenue streams: (1) CRO services — antiviral discovery (compound screening, mechanism-of-action studies, SAR optimization, in vivo validation against a 1,200 FDA-approved compound library), oncolytic virotherapy development (design, cell line testing, in vivo testing, drug combinations, virogram analysis), disinfection efficacy testing (chemical, UV-C, ozone, radiative on surfaces and living skin), and high-resolution imaging; (2) ANCHOR™ technology licensing via Material Transfer Agreements in tiered packs (Discovery €1,000, Complete €2,000, Advanced €4,000) for perpetual use; and (3) proprietary antiviral compound development (notably the LAVR-289 family and nitrocorroles) for out-licensing. Customer acquisition is sales-led, supported by industry conference participation (Eurosatory, ICAR), scientific publication, technology transfer partnerships (SAYENS, Toulouse Tech Transfer), and strategic alliances with VirexpR, VirHealth, Imactiv-3D, and BioImmunitas.

NeoVirTech serves pharmaceutical and biotechnology companies, oncology developers, medical device and disinfection manufacturers, government and defense agencies (notably French Armed Forces for poxvirus countermeasures), gene therapy developers, and academic institutions — a horizontal segmentation across approximately 86 worldwide customers. The company holds 10 patents protecting the ANCHOR™ platform and related compounds, has received successive French innovation grants (I-Lab 2013 and 2016, AID 2020, Occitanie 2021, France 2030 Perseverance 2024), and was recognized by PharmaTech Outlook as a Top 10 European Drug Discovery and Development Company in 2019. Ownership remains private with founder Franck Gallardo as CEO; no private equity backing has been disclosed.

Short descriptiontext

NeoVirTech is a French biotechnology CRO offering proprietary ANCHOR™ DNA tagging technology for real-time visualization of viral infection in living cells, serving pharmaceutical, biotech, medical device, defense, and academic customers with antiviral discovery, oncolytic virotherapy development, and disinfection testing services.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersToulouse, France
HQ citystring
Toulouse
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antiviral drug discovery, virology research services, contract research organization, oncolytic virotherapy, disinfection efficacy testing
Industry2 codes
PRIMARYHLAGAAAE
Central Laboratory & Clinical Trial Testing CROs
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Virology Contract Research Services
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model5 records
1CRO Services - Antiviral Discovery
TypeProfessional Services
Description

Contract research services for pharmaceutical and biotech companies including compound screening, mechanism of action studies, SAR (Structure-Activity Relationship) studies, and in vivo validation. Multi-year screening and optimization campaigns for public agencies and private companies.

neovirtech.com
2CRO Services - Disinfection Testing
TypeProfessional Services
Description

Testing services for chemical, physical, and radiative disinfection processes on viruses. Calibration and validation of disinfection devices for companies. Normative testing according to FR/EN/ASTM standards through VirHealth partnership.

neovirtech.com
3CRO Services - Oncolytic Virus Development
TypeProfessional Services
Description

Preclinical development services for oncolytic viruses including cell line efficiency testing, in vivo testing, drug combination studies, and virogram analysis on cancer cell lines.

neovirtech.com
4ANCHOR™ Technology Licensing
TypeLicensing Royalties
Description

Licensing fees for technology access including Discovery Pack (trial version, €1000, 6-month MTA), Complete Pack (all systems, €2000), and Advanced Pack (with autofluorescent virus, €4000). MTA (Material Transfer Agreement) based licensing.

neovirtech.com
5Proprietary Antiviral Compounds
TypeLicensing Royalties
Description

Development and positioning of proprietary products displaying broad spectrum antiviral activities on emerging markets.

neovirtech.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Pricing details3 tiers
1Discovery Pack (Trial) - €1,000
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

One ANCHOR system, 6-month MTA duration, restricted use of modifications. Transfer to complete pack available with only difference payment.

neovirtech.com
2Complete Pack - €2,000
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

All available ANCHOR systems (4 constructs, several colors), unlimited use of modifications.

neovirtech.com
3Advanced Pack - €4,000
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Complete pack plus one available autofluorescent virus, unlimited use of modifications and virus.

neovirtech.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

NeoVirTech SAS is a contract research organization (CRO) that delivers specialized virology research services, including antiviral drug discovery, oncolytic virotherapy development, disinfection efficacy testing, and live-cell imaging, executed in BSL2 and BSL3 laboratories. Its proprietary ANCHOR™ technology enables real-time visualization of DNA in living cells, supporting both fee-for-service research and technology licensing engagements.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Visualization of single DNA molecules in living cells (up to 500 OR-FP/ANCH accumulation)
+4 more records
Product overview1 text field

NeoVirTech operates as a biotechnology CRO offering a platform of services centered on its proprietary ANCHOR™ autofluorescent virus technology. The core offering consists of the ANCHOR™ Technology platform and an expanding collection of 32 ANCHOR™-tagged viruses for real-time visualization of infection and replication. Service modules include antiviral drug discovery (screening through in vivo validation), oncolytic virotherapy development (design through preclinical testing), high content screening platform, high-resolution imaging, and disinfection efficacy testing. The company also offers access to BSL2/BSL3 laboratory facilities. Recent additions include an oncolytic viruses platform and airborne disinfection testing capabilities developed through strategic partnerships.

Product and service1 record
1Antiviral Drug Discovery
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-03
Description

Expanded collaboration to develop experimental test bench model for airborne poxvirus contamination. VirexpR uses VACV ANCHOR poxvirus (labeled 'used by French Armed Forces' in 2024) as mimetic model to characterize infectious bioaerosols using various test benches for air treatment technology evaluation under real conditions.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-03-01
Description

Collaboration for 3D imaging and analysis of infected spheroids. Imactiv-3D provides imaging expertise and custom algorithms for quantification. Partnership enables complex 3D model analysis including infected spheroids to whole insects.

3ImPACT Team (CRCT)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-03-01
Description

Part of Perseverance program (France 2030 funded) to develop theranostic platform for cancer virotherapies. Collaboration for preclinical development of oncolytic viruses with arming strategies.

neovirtech.com
4National Veterinary School of Toulouse (ENVT)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-03-01
Description

Part of Perseverance program for cancer virotherapy development. Long-standing collaboration for application of ANCHOR technology to poxviruses of veterinary interest and animal herpesvirus tagging.

neovirtech.com
5CHU de Toulouse / Oncopole Claudius Régaud
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-03-01
Description

Clinical partner in Perseverance program (France 2030) for theranostic platform development. Provides patient tumor organoid models and clinical expertise for oncolytic virotherapy validation.

neovirtech.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-02-27
Description

Strategic alliance combining NeoVirTech's autofluorescent viruses with VirexpR's nebulization technologies for airborne disinfection testing. Uses VirexpR's 2.5m³ and 20m³ nebulization chambers to disperse VACV ANCHOR poxvirus and measure air treatment device efficiency using image-based readout. Partnership allows measurement and visualization of airborne disinfection efficacy and respiratory protection testing.

7BioImmunitas Ltd
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-02-21
Description

Long-term partnership to advance BioImmunitas's human recombinant protein (hRP) therapeutic platform using NeoVirTech's antiviral discovery platform to position the therapeutic on anti-viral market. BioImmunitas utilizes NVT's proprietary platform for antiviral compound testing and validation.

neovirtech.com
8Teco Labs
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-01-01
Description

Partnership agreement signed in 2023 to develop NeoVirTech's activity in the Asian market through distribution and partnership facilitation.

neovirtech.com
9Cancer Research Center of Toulouse (CRCT)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-03-15
Description

NeoVirTech opened laboratory at CRCT to structure anti-cancer programs toward patient-oriented theranostics platform. Collaboration with CRCT Team 10 to develop rapid theranostic platform for oncolytic virotherapy efficacy. Long-term collaboration to ensure patient benefits and reduce time to decision for individualized cancer therapies.

neovirtech.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-03-11
Description

Strategic alliance creating one of the most advanced private virus disinfection platforms in Europe. Combines virology expertise to provide customers with extended virus disinfection measurement and R&D platform. Focus on virus persistence in environment, disinfection procedures, and standardized measurement approaches according to FR/EN/ASTM standards.

11Transgene SA
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Ongoing collaboration since 2016 for development of ANCHOR-tagged oncolytic viruses. Transgene is a biopharmaceutical company developing targeted immunotherapies. NeoVirTech provides high-resolution quantitative microscopy for product visualization and validation.

neovirtech.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-11-01
Description

Long-term collaboration with French Technology Transfer Accelerator for development of broad spectrum antivirals for human and animal health. Led to generation of 200+ antiviral variants with nM activity and selectivity indexes over 500, resulting in 2 international patent filings.

13Institut de Recherche Biomédical des Armées (IRBA)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Collaboration for testing antivirals against poxviruses during 2022 Mpox emergence. Also collaboration for risk mitigation in BSL4 laboratory work with VACV ANCHOR virus.

neovirtech.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Specialized infectious disease and virology CRO with BSL3 containment for in vivo and in vitro viral studies. Comparable to NeoVirTech in offering virology-specific CRO services to pharma, biotech, and government clients with biosafety-level capabilities.

TypeEmerging player
Description

Clinical-stage immunology company developing antiviral therapies for infectious diseases including influenza, hepatitis B, and HIV. Comparable to NeoVirTech in deep virology expertise and infectious disease focus, though operating as a product developer rather than a CRO.

TypeBroad incumbent
Description

Global testing services group with virology, disinfection efficacy, and pharma testing offerings. Comparable to NeoVirTech in offering standardized disinfection validation testing (FR/EN/ASTM) and virology testing services, but at much larger scale.

TypeBroad incumbent
Description

European-headquartered drug discovery CRO with antiviral and infectious disease programs. Comparable to NeoVirTech in CRO-based antiviral discovery, but with substantially broader service portfolio and larger bench footprint.

TypeBroad incumbent
Description

Large global preclinical CRO with established virology, BSL3, and antiviral testing services. Comparable to NeoVirTech in offering antiviral discovery and biosafety-level laboratory services, but operates at vastly greater scale and across many therapeutic areas beyond virology.

TypeDirect peer
Description

US-based CRO specializing in virology, antiviral, and infectious disease preclinical services with BSL3 capabilities. Highly comparable to NeoVirTech in virology-focused CRO offering, biosafety-level access, and antiviral screening services for pharma and biotech clients.

TypeDirect peer
Description

Non-profit CRO with BSL3 facilities and antiviral/infectious disease screening capabilities. Comparable to NeoVirTech in specialized virology CRO work for government and biodefense clients, including pandemic preparedness programs.

TypeEmerging player
Description

French airborne disinfection testing specialist using nebulization chambers. Direct strategic partner to NeoVirTech on airborne poxvirus contamination testing; comparable in disinfection testing focus but specialized on airborne/aerosol delivery rather than live-cell imaging.

TypeBroad incumbent
Description

Preclinical CRO offering research models, toxicology, and discovery services including infectious disease work. Comparable to NeoVirTech in preclinical CRO services for life sciences clients, though broader in scope and without the proprietary imaging moat.

10Transgene SA
TypeEmerging player
Description

French biopharmaceutical company developing oncolytic virotherapies and immunotherapies; long-term NeoVirTech partner since 2016. Comparable in that it is a customer and collaborator on ANCHOR-tagged oncolytic virus development, not a direct CRO competitor.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Neovirtech

Virology Contract Research Servicesneovirtech.com

NeoVirTech is a French biotechnology CRO offering proprietary ANCHOR™ DNA tagging technology for real-time visualization of viral infection in living cells, serving pharmaceutical, biotech, medical device, defense, and academic customers with antiviral discovery, oncolytic virotherapy development, and disinfection testing services.

What Neovirtech does

NeoVirTech SAS is a French biotechnology Contract Research Organization (CRO) founded in February 2014 and headquartered at the Oncopole campus in Toulouse, with an additional R&D laboratory at the Toulouse Cancer Research Center (CRCT) opened in 2022. The company commercializes its proprietary ANCHOR™ DNA tagging technology — a system that fuses a short non-repetitive ANCH sequence with an OR-fluorescent protein to convert any dsDNA virus or vector into an autofluorescent particle, enabling autonomous real-time visualization of viral infection and replication in living cells without fixation, extraction, or staining. Multiple ANCHOR™ systems (up to four colors) can be operated simultaneously for co-infection studies, and the company maintains a catalog of 32 ANCHOR-tagged viruses spanning human, animal, and biodefense applications. Core technical infrastructure includes dual BSL2/BSL3 containment, automated CellInsight CX7 HCS high-content screening, pipetting robots, and a 22TB secured server, all of which underwrite both internal R&D and customer service delivery.

The company monetizes through three revenue streams: (1) CRO services — antiviral discovery (compound screening, mechanism-of-action studies, SAR optimization, in vivo validation against a 1,200 FDA-approved compound library), oncolytic virotherapy development (design, cell line testing, in vivo testing, drug combinations, virogram analysis), disinfection efficacy testing (chemical, UV-C, ozone, radiative on surfaces and living skin), and high-resolution imaging; (2) ANCHOR™ technology licensing via Material Transfer Agreements in tiered packs (Discovery €1,000, Complete €2,000, Advanced €4,000) for perpetual use; and (3) proprietary antiviral compound development (notably the LAVR-289 family and nitrocorroles) for out-licensing. Customer acquisition is sales-led, supported by industry conference participation (Eurosatory, ICAR), scientific publication, technology transfer partnerships (SAYENS, Toulouse Tech Transfer), and strategic alliances with VirexpR, VirHealth, Imactiv-3D, and BioImmunitas.

NeoVirTech serves pharmaceutical and biotechnology companies, oncology developers, medical device and disinfection manufacturers, government and defense agencies (notably French Armed Forces for poxvirus countermeasures), gene therapy developers, and academic institutions — a horizontal segmentation across approximately 86 worldwide customers. The company holds 10 patents protecting the ANCHOR™ platform and related compounds, has received successive French innovation grants (I-Lab 2013 and 2016, AID 2020, Occitanie 2021, France 2030 Perseverance 2024), and was recognized by PharmaTech Outlook as a Top 10 European Drug Discovery and Development Company in 2019. Ownership remains private with founder Franck Gallardo as CEO; no private equity backing has been disclosed.

Neovirtech firmographics

Firmographics
Name
Neovirtech
Legal name
NeoVirTech SAS
Website
https://neovirtech.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
1–10 employees
Short description
NeoVirTech is a French biotechnology CRO offering proprietary ANCHOR™ DNA tagging technology for real-time visualization of viral infection in living cells, serving pharmaceutical, biotech, medical device, defense, and academic customers with antiviral discovery, oncolytic virotherapy development, and disinfection testing services.
Ownership category
akta.pro rank

Neovirtech industry classification

Industry
Product category
Virology Contract Research Services
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAE
Central Laboratory & Clinical Trial Testing CROs
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)

Keywords

  • Antiviral drug discovery
  • Virology research services
  • Contract research organization
  • Oncolytic virotherapy
  • Disinfection efficacy testing

Where Neovirtech is headquartered

Location

Headquarters

HQ city
Toulouse
HQ country
France
HQ region
Europe

Offices2 records

Markets served

Neovirtech business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. CRO Services - Antiviral Discovery: Contract research services for pharmaceutical and biotech companies including compound screening, mechanism of action studies, SAR (Structure-Activity Relationship) studies, and in vivo validation. Multi-year screening and optimization campaigns for public agencies and private companies.
  2. CRO Services - Disinfection Testing: Testing services for chemical, physical, and radiative disinfection processes on viruses. Calibration and validation of disinfection devices for companies. Normative testing according to FR/EN/ASTM standards through VirHealth partnership.
  3. CRO Services - Oncolytic Virus Development: Preclinical development services for oncolytic viruses including cell line efficiency testing, in vivo testing, drug combination studies, and virogram analysis on cancer cell lines.
  4. ANCHOR™ Technology Licensing: Licensing fees for technology access including Discovery Pack (trial version, €1000, 6-month MTA), Complete Pack (all systems, €2000), and Advanced Pack (with autofluorescent virus, €4000). MTA (Material Transfer Agreement) based licensing.
  5. Proprietary Antiviral Compounds: Development and positioning of proprietary products displaying broad spectrum antiviral activities on emerging markets.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goDiscovery Pack (Trial) - €1,000
One time/ perpetual licensePay-as-you-goComplete Pack - €2,000
One time/ perpetual licensePay-as-you-goAdvanced Pack - €4,000

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

Neovirtech product offering

Product offering

Core offering

NeoVirTech SAS is a contract research organization (CRO) that delivers specialized virology research services, including antiviral drug discovery, oncolytic virotherapy development, disinfection efficacy testing, and live-cell imaging, executed in BSL2 and BSL3 laboratories. Its proprietary ANCHOR™ technology enables real-time visualization of DNA in living cells, supporting both fee-for-service research and technology licensing engagements.

Product overview

NeoVirTech operates as a biotechnology CRO offering a platform of services centered on its proprietary ANCHOR™ autofluorescent virus technology. The core offering consists of the ANCHOR™ Technology platform and an expanding collection of 32 ANCHOR™-tagged viruses for real-time visualization of infection and replication. Service modules include antiviral drug discovery (screening through in vivo validation), oncolytic virotherapy development (design through preclinical testing), high content screening platform, high-resolution imaging, and disinfection efficacy testing. The company also offers access to BSL2/BSL3 laboratory facilities. Recent additions include an oncolytic viruses platform and airborne disinfection testing capabilities developed through strategic partnerships.

Differentiator

Problem solved

Functional benefit

Products and services

  • Antiviral Drug Discovery

Quantifiable outcome

  • Visualization of single DNA molecules in living cells (up to 500 OR-FP/ANCH accumulation)
  • +4 more outcomes

Companies that use Neovirtech

Customer profile

Named customers6 records

Segments6 records

Ideal customer profiles3 records

Neovirtech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Neovirtech partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered core and minor.

  • VirexpR SAScoreStrategic or Co-development Partner · 3 September 2024Expanded collaboration to develop experimental test bench model for airborne poxvirus contamination. VirexpR uses VACV ANCHOR poxvirus (labeled 'used by French Armed Forces' in 2024) as mimetic model to characterize infectious bioaerosols using various test benches for air treatment technology evaluation under real conditions.
  • Imactiv-3DcoreTechnology or Integration · 1 March 2024Collaboration for 3D imaging and analysis of infected spheroids. Imactiv-3D provides imaging expertise and custom algorithms for quantification. Partnership enables complex 3D model analysis including infected spheroids to whole insects.
  • ImPACT Team (CRCT)coreStrategic or Co-development Partner · 1 March 2024Part of Perseverance program (France 2030 funded) to develop theranostic platform for cancer virotherapies. Collaboration for preclinical development of oncolytic viruses with arming strategies.
  • National Veterinary School of Toulouse (ENVT)coreStrategic or Co-development Partner · 1 March 2024Part of Perseverance program for cancer virotherapy development. Long-standing collaboration for application of ANCHOR technology to poxviruses of veterinary interest and animal herpesvirus tagging.
  • CHU de Toulouse / Oncopole Claudius RégaudcoreStrategic or Co-development Partner · 1 March 2024Clinical partner in Perseverance program (France 2030) for theranostic platform development. Provides patient tumor organoid models and clinical expertise for oncolytic virotherapy validation.
  • VirexpR SAScoreStrategic or Co-development Partner · 27 February 2023Strategic alliance combining NeoVirTech's autofluorescent viruses with VirexpR's nebulization technologies for airborne disinfection testing. Uses VirexpR's 2.5m³ and 20m³ nebulization chambers to disperse VACV ANCHOR poxvirus and measure air treatment device efficiency using image-based readout. Partnership allows measurement and visualization of airborne disinfection efficacy and respiratory protection testing.
  • BioImmunitas LtdcoreStrategic or Co-development Partner · 21 February 2023Long-term partnership to advance BioImmunitas's human recombinant protein (hRP) therapeutic platform using NeoVirTech's antiviral discovery platform to position the therapeutic on anti-viral market. BioImmunitas utilizes NVT's proprietary platform for antiviral compound testing and validation.
  • Teco LabsminorChannel Partner/ Reseller/ Distributor · 1 January 2023Partnership agreement signed in 2023 to develop NeoVirTech's activity in the Asian market through distribution and partnership facilitation.
  • Cancer Research Center of Toulouse (CRCT)coreStrategic or Co-development Partner · 15 March 2022NeoVirTech opened laboratory at CRCT to structure anti-cancer programs toward patient-oriented theranostics platform. Collaboration with CRCT Team 10 to develop rapid theranostic platform for oncolytic virotherapy efficacy. Long-term collaboration to ensure patient benefits and reduce time to decision for individualized cancer therapies.
  • VirHealth SAScoreStrategic or Co-development Partner · 11 March 2022Strategic alliance creating one of the most advanced private virus disinfection platforms in Europe. Combines virology expertise to provide customers with extended virus disinfection measurement and R&D platform. Focus on virus persistence in environment, disinfection procedures, and standardized measurement approaches according to FR/EN/ASTM standards.
  • Transgene SAcoreStrategic or Co-development Partner · 1 January 2022Ongoing collaboration since 2016 for development of ANCHOR-tagged oncolytic viruses. Transgene is a biopharmaceutical company developing targeted immunotherapies. NeoVirTech provides high-resolution quantitative microscopy for product visualization and validation.
  • SAYENScoreStrategic or Co-development Partner · 1 November 2021Long-term collaboration with French Technology Transfer Accelerator for development of broad spectrum antivirals for human and animal health. Led to generation of 200+ antiviral variants with nM activity and selectivity indexes over 500, resulting in 2 international patent filings.
  • Institut de Recherche Biomédical des Armées (IRBA)coreStrategic or Co-development Partner · 1 January 2020Collaboration for testing antivirals against poxviruses during 2022 Mpox emergence. Also collaboration for risk mitigation in BSL4 laboratory work with VACV ANCHOR virus.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Neovirtech competitors and assessment

Company assessment

Direct peers

  • BIOQUAL: Specialized infectious disease and virology CRO with BSL3 containment for in vivo and in vitro viral studies. Comparable to NeoVirTech in offering virology-specific CRO services to pharma, biotech, and government clients with biosafety-level capabilities.
  • ImQuest Biosciences: US-based CRO specializing in virology, antiviral, and infectious disease preclinical services with BSL3 capabilities. Highly comparable to NeoVirTech in virology-focused CRO offering, biosafety-level access, and antiviral screening services for pharma and biotech clients.
  • Southern Research: Non-profit CRO with BSL3 facilities and antiviral/infectious disease screening capabilities. Comparable to NeoVirTech in specialized virology CRO work for government and biodefense clients, including pandemic preparedness programs.

Emerging players

  • Vir Biotechnology: Clinical-stage immunology company developing antiviral therapies for infectious diseases including influenza, hepatitis B, and HIV. Comparable to NeoVirTech in deep virology expertise and infectious disease focus, though operating as a product developer rather than a CRO.
  • VirexpR SAS: French airborne disinfection testing specialist using nebulization chambers. Direct strategic partner to NeoVirTech on airborne poxvirus contamination testing; comparable in disinfection testing focus but specialized on airborne/aerosol delivery rather than live-cell imaging.
  • Transgene SA: French biopharmaceutical company developing oncolytic virotherapies and immunotherapies; long-term NeoVirTech partner since 2016. Comparable in that it is a customer and collaborator on ANCHOR-tagged oncolytic virus development, not a direct CRO competitor.

Broad incumbents

  • Eurofins Scientific: Global testing services group with virology, disinfection efficacy, and pharma testing offerings. Comparable to NeoVirTech in offering standardized disinfection validation testing (FR/EN/ASTM) and virology testing services, but at much larger scale.
  • Evotec SE: European-headquartered drug discovery CRO with antiviral and infectious disease programs. Comparable to NeoVirTech in CRO-based antiviral discovery, but with substantially broader service portfolio and larger bench footprint.
  • Charles River Laboratories: Large global preclinical CRO with established virology, BSL3, and antiviral testing services. Comparable to NeoVirTech in offering antiviral discovery and biosafety-level laboratory services, but operates at vastly greater scale and across many therapeutic areas beyond virology.
  • Inotiv Inc: Preclinical CRO offering research models, toxicology, and discovery services including infectious disease work. Comparable to NeoVirTech in preclinical CRO services for life sciences clients, though broader in scope and without the proprietary imaging moat.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Neovirtech social profiles

Digital presence

Neovirtech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Neovirtech leadership team

Management profile

Number of profiles

Profiles1 record

Neovirtech funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Neovirtech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neovirtech

What does Neovirtech do?

NeoVirTech SAS is a contract research organization (CRO) that delivers specialized virology research services, including antiviral drug discovery, oncolytic virotherapy development, disinfection efficacy testing, and live-cell imaging, executed in BSL2 and BSL3 laboratories. Its proprietary ANCHOR™ technology enables real-time visualization of DNA in living cells, supporting both fee-for-service research and technology licensing engagements.

Is Neovirtech a public or private company?

Neovirtech is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Neovirtech founded?

Neovirtech was founded in 2014. It employs 1 to 10 people.

Where is Neovirtech based?

Neovirtech is headquartered in Toulouse, France, in the Europe region.

How does Neovirtech make money?

Five revenue lines are on record. CRO Services - Antiviral Discovery is the primary driver. The others are CRO Services - Disinfection Testing, CRO Services - Oncolytic Virus Development, ANCHOR™ Technology Licensing and proprietary Antiviral Compounds.

Who are Neovirtech's main competitors?

Direct peers on record are BIOQUAL, ImQuest Biosciences and Southern Research. Emerging players are Vir Biotechnology, VirexpR SAS and Transgene SA. Broad incumbents are Eurofins Scientific, Evotec SE, Charles River Laboratories and Inotiv Inc.

Does Neovirtech have an API?

No public API is recorded for Neovirtech.

What industry is Neovirtech in?

Neovirtech's product category is Virology Contract Research Services. Its primary akta.pro industry code is HLAGAAAE, Central Laboratory & Clinical Trial Testing CROs, with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales